Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Penicillamine 250mg tablets
1001030F0AAAFAF
|
Penicillamine | Penicillamine | Musculoskeletal and Joint Diseases | 1,520 |
|
Penicillamine 125mg tablets
1001030F0AAAEAE
|
Penicillamine | Penicillamine | Musculoskeletal and Joint Diseases | 598 |
|
Distamine 125mg tablets
1001030F0BBABAE
|
Distamine | Penicillamine | Musculoskeletal and Joint Diseases | No data available |
|
Distamine 250mg tablets
1001030F0BBACAF
|
Distamine | Penicillamine | Musculoskeletal and Joint Diseases | No data available |
|
Metalcaptase gastro-resistant 150mg tablets
1001030F0BDAAAM
|
Metalcaptase | Penicillamine | Musculoskeletal and Joint Diseases | No data available |
|
Metalcaptase gastro-resistant 300mg tablets
1001030F0BDABAN
|
Metalcaptase | Penicillamine | Musculoskeletal and Joint Diseases | No data available |
|
Penicillamine 125mg/5ml oral solution
1001030F0AAAJAJ
|
Penicillamine | Penicillamine | Musculoskeletal and Joint Diseases | No data available |
|
Penicillamine 250mg/5ml oral solution
1001030F0AAAIAI
|
Penicillamine | Penicillamine | Musculoskeletal and Joint Diseases | No data available |
|
Penicillamine 250mg/5ml oral suspension
1001030F0AAALAL
|
Penicillamine | Penicillamine | Musculoskeletal and Joint Diseases | No data available |
|
Penicillamine 50mg/5ml oral solution
1001030F0AAAKAK
|
Penicillamine | Penicillamine | Musculoskeletal and Joint Diseases | No data available |
|
Penicillamine gastro-resistant 150mg tablets
1001030F0AAAMAM
|
Penicillamine | Penicillamine | Musculoskeletal and Joint Diseases | No data available |
|
Penicillamine gastro-resistant 300mg tablets
1001030F0AAANAN
|
Penicillamine | Penicillamine | Musculoskeletal and Joint Diseases | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.